Ignite Creation Date:
2024-05-05 @ 5:05 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00387751
Status:
COMPLETED
Last Update Posted:
2017-11-22
First Post:
2006-10-12
Brief Title:
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Organization Data
Organization:
National Cancer Institute NCI
Class:
NIH
Study ID:
NCI-2009-00134
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Cancer Institute NCI
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None